The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Eli Lilly, the manufacturer, said Friday that Zepbound should be used for treatment of moderate to severe obstructive sleep ...

There are many breakthroughs in medicine regarding the treatment of obstructive sleep apnea, and a weight loss drug might ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The Food and Drug Administration announced late Friday that it has approved Zepbound to treat obstructive sleep apnea for ...

Nocturnal enuresis is more common in children with obstructive sleep apnea (OSA), according to a study published online Sept. 23 in Children. In a new analysis of national data, researchers at the ...

Continuous positive airway pressure (CPAP) therapy significantly benefits individuals with obstructive sleep apnea. However, nearly half of adults with CPAP devices struggle to maintain consistent ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that its weight loss treatment, Zepbound (tirzepatide), outperformed Novo ...

phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: ...

Zepbound is a dual GIP and GLP-1 receptor ... Tirzepatide is also being developed for other indications like obstructive sleep apnea, heart failure with preserved ejection fraction, cardiovascular ...